Hokkaido Gastrointestinal Cancer Study Group
12
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
16.7%
2 terminated/withdrawn out of 12 trials
66.7%
-19.8% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
Role: lead
Phase I/II Study of Taxotere,CDDP and 5-FU(TPF) in Pre-treated Pts With Metastatic Esophageal Cancer.
Role: lead
Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.
Role: lead
Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer
Role: lead
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
Role: lead
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Role: lead
Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer
Role: lead
IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer
Role: lead
Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal Cancer
Role: lead
Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Role: lead
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
Role: lead
Phase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
Role: lead
All 12 trials loaded